Skip to main
RLAY

RLAY Stock Forecast & Price Target

RLAY Analyst Ratings

Based on 11 analyst ratings
Buy
Strong Buy 45%
Buy 45%
Hold 9%
Sell 0%
Strong Sell 0%

Bulls say

Relay Therapeutics is a clinical-stage precision medicine company with a strong pipeline of candidates focused on targets in precision oncology and genetic disease. The company utilizes its unique Dynamo platform, which integrates advanced computational and experimental approaches, to design and develop new drugs that target previously intractable or inadequately addressed protein targets. The recent positive results from the clinical trials for its lead candidate, zovegalisib, demonstrate its potential to significantly improve upon existing treatments, while the broad potential of its technology opens up opportunities in multiple disease areas. With a solid financial position and a strong team, Relay Therapeutics is well-positioned for success in the long term.

Bears say

Relay Therapeutics is facing multiple challenges due to concerns over the impact of one of its drugs, Alpelisib, on pediatric growth. In addition, there may be limited room for further improvement and potential competition in the market, putting pressure on the stock. Furthermore, the company's reliance on future financing could lead to dilution for existing shareholders, creating financial risk.

RLAY has been analyzed by 11 analysts, with a consensus rating of Buy. 45% of analysts recommend a Strong Buy, 45% recommend Buy, 9% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Relay Therapeutics, Inc. and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Relay Therapeutics, Inc. (RLAY) Forecast

Analysts have given RLAY a Buy based on their latest research and market trends.

According to 11 analysts, RLAY has a Buy consensus rating as of Jul 18, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $24, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $24, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Relay Therapeutics, Inc. (RLAY)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.